Feasibility and efficacy of preoperative chemoradiation and postoperative liver perfusion chemotherapy for T3 (UICC) pancreatic cancer

Conditions

Pancreatic cancer

Hidenori Takahashi, Hiroaki Ohigashi, Kunihito Gotoh, Shigeru Marubashi, Terumasa Yamada et al. (10 authors)

Annals of Surgery2013-06-25167 citations

Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer.

Takahashi H, Ohigashi H, Ishikawa O, Gotoh K, Yamada T, Nagata S, Tomita Y, Eguchi H, Doki Y, Yano M.

2012-01-0198 citations

10.1097/sla.0b013e31823d813c

Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.

Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, Yano M, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K.

2009-07-0191 citations

10.1097/sla.0b013e3181ad65cc

Interventions

Chemoradiation EXRT 50Gy gemcitabine 1000mg/m2 Liver perfusion chemotherapy 5FU 125mg/day via hepatic artery, 125mg/day via portal vein for 4 weeks (continuous infusion) or gemcitabine 1g via porta

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pancreatic cancer ; T3 of UICC TNM classification of malignant tumours 6th edition) Histological or cytological confirmation as pancreatic adenocarcinoma Performance status (ECOG) is 0 or 1

Exclusion criteria

Exclusion criteria: unusual running of hepatic artery, renal dysfunction, sever coronary disease, past history of malignant disease or chronic hepatitis, white blood cell count<3000/mm3, platelet count <104/mm3, Activated partial thromboplastin>50sec, ALT,AST>100U/l creatinine>1.5mg/dl

Design outcomes

Primary

Measure	Time frame
safety, survival	—

Secondary

Measure	Time frame
pathological response, pattern of failure	—

Countries

Japan

Contacts

Public ContactHiroaki Ohigashi

Osaka Medical Center for cancer & Cardiovascular Diseases gastrointestinal & hepatobiliary- pancreatic surgery

06-6972-1181

Outcome results

None listed